Prognosis research strategy (PROGRESS) 4: Stratified medicine research

BMJ (Online)

Volumn 346, Issue , 2013, Pages

  Hingorani, Aroon D ^a   Van Der Windt, Daniëlle A ^b   Riley, Richard D ^c   Abrams, Keith ^d   Moons, Karel G M ^e   Steyerberg, Ewout W ^f   Schroter, Sara ^g   Sauerbrei, Willi ^h   Altman, Douglas G ⁱ   Hemingway, Harry ^a   Briggs, Andrew ^j   Brunner, Nils ^j   Croft, Peter ^j   Hayden, Jill ^j   Kyzas, Panayiotis ^j   Malats, Núria ^j   Peat, George ^j   Perel, Pablo ^j   Roberts, Ian ^j   Timmis, Adam ^j  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g BMJ   (United Kingdom)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEALTH SERVICES RESEARCH; HUMAN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; MEDICINE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; RESEARCH PRIORITY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRATEGIC PLANNING; STRATIFIED MEDICINE; STUDY DESIGN; SYSTEMATIC ERROR; TREATMENT PLANNING; BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DIAGNOSTIC PROCEDURE; ECONOMICS; FINANCIAL MANAGEMENT; LABORATORY DIAGNOSIS; METHODOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT;

BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DELIVERY OF HEALTH CARE; DIAGNOSTIC TECHNIQUES AND PROCEDURES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HEALTH POLICY; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; RISK ASSESSMENT; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

MLCS; MLOWN;

EID: 84874455291     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e5793     Document Type: Article

References (55)

1. Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013;346:e5595.
2. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
3. Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. Prognosis research strategy (PROGRESS) 2: Prognostic factor research. PLoS Med 2013, doi:10.1371.journal/pmed.1001380.
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45. (Pubitemid 350003059)
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
6. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301-4.
7. House of Lords Science and Technology Committee. Genomic medicine. Volume II: evidence. Stationery Office, 2009. www.publications.parliament.uk/pa/ ld200809/ldselect/ ldsctech/107/107ii.pdf
8. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov 2007;6:287-93. (Pubitemid 46505879)
9. Rothwell PM, Mehta Z, Howard SC, Gutnikov SA, Warlow CP. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 2005;365:256-65. (Pubitemid 40138020)
10. Steyerberg EW, Moons KGM, van der Windt DA, Hayden JA, Perel P, Schroter S, et al. Prognosis research strategy (PROGRESS) 3: prognostic model research. PLoS Med 2013, doi:10.1371.journal/pmed.1001381.
11. Hingorani AD, Hemingway H. How should we balance individual and population benefits of statins for preventing cardiovascular disease? BMJ 2011;342:c6244.
12. Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster NE, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet 2011;378:1560-71.
13. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493-502.
14. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
15. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32. (Pubitemid 34215071)
16. Flynn MR, Barrett C, Cosio FG, Gitt AK, Wallentin L, Kearney P, et al. The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice. Eur Heart J 2005;26:308-13. (Pubitemid 40227433)
17. Brennan GP, Fritz JM, Hunter SJ, Thackeray A, Delitto A, Erhard RE. Identifying subgroups of patients with acute/subacute "nonspecific" low back pain: results of a randomized clinical trial. Spine 2006;31:623-31.
18. Childs JD, Fritz JM, Flynn TW, Irrgang JJ, Johnson KK, Majkowski GR, et al. A clinical prediction rule to identify patients with low back pain most likely to benefit from spinal manipulation: a validation study. Ann Intern Med 2004;141:920-8.
19. Von KM, Moore JC. Stepped care for back pain: activating approaches for primary care. Ann Intern Med 2001;134:911-7. (Pubitemid 32405700)
20. Almirall D, Compton SN, Gunlicks-Stoessel M, Duan N, Murphy SA. Designing a pilot sequential multiple assignment randomized trial for developing an adaptive treatment strategy. Stat Med 2012;31:1887-902.
21. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17. (Pubitemid 43250663)
22. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406-12.
23. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64.
24. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
25. Royston P, Sauerbrei W, Ritchie A. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 2004;90:794-9. (Pubitemid 38406588)
26. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7:97-104. (Pubitemid 40261834)
27. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009;24:656-64.
28. Henderson R, Keiding N. Individual survival time prediction using statistical models. J Med Ethics 2005;31:703-6. (Pubitemid 43013381)
29. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MSV, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16.
30. Moons KG. Criteria for scientific evaluation of novel markers: a perspective. Clin Chem 2010;56:537-41.
31. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 2008;19:487-95. (Pubitemid 351325669)
32. Williams AH, Cookson RA. Equity-efficiency trade-offs in health technology assessment. Int J Technol Assess Health Care 2006;22:1-9. (Pubitemid 43376233)
33. Woelderink A, Ibarreta D, Hopkins MM, Rodriguez-Cerezo E. The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies. Pharmacogenomics J 2006;6:3-7. (Pubitemid 43118304)
34. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists guidelines for human epidermal growth factor receptor 2 testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med 2010;134:728-34.
35. Danese MD, Lalla D, Brammer M, Doan Q, Knopf K. Estimating recurrences prevented from using trastuzumab in HER-2/neu-positive adjuvant breast cancer in the United States. Cancer 2010 15;116:5575-83.
36. Li Y, Iakoubova OA, Shiffman D, Devlin JJ, Forrester JS, Superko HR. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am J Cardiol 2010;106:994-8.
37. Assimes TL, Holm H, Kathiresan S, Reilly MP, Thorleifsson G, Voight BF, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol 2010;56:1552-63.
38. Fayers PM, King MT. How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses. Qual Life Res 2009;18:527-30.
39. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol 2007;3:407-13. (Pubitemid 47034542)
40. Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:5512-28. (Pubitemid 351193578)
41. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ 2010;340:c117.
42. Willett WC. The search for truth must go beyond statistics. Epidemiology 2008;19:655-6.
43. Sauerbrei W, Royston P. Modelling to extract more information from clinical trials data: on some roles for the bootstrap. Stat Med 2007;26:4989-5001. (Pubitemid 350064918)
44. Guyatt G, Rennie D, Meade M, Cook D. When to believe a subgroup analysis. In: Users' guides to the medical literature: a manual for evidence-based clinical practice. 2nd ed. AMA Press, 2008.
45. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
46. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221.
47. Royston P, Sauerbrei W. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials. Stat Med 2004;23:2509-25. (Pubitemid 39149264)
48. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9. (Pubitemid 30162810)
49. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219. (Pubitemid 36143396)
50. Holmes MV, Shah T, Vickery C, Smeeth L, Hingorani AD, Casas JP. Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PLoS One 2009;4:e7960.
51. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127-41. (Pubitemid 43136953)
52. Senn S. Individual response to treatment: is it a valid assumption? BMJ 2004;329:966-8. (Pubitemid 39422915)
53. Riley RD, Lambert PC, Staessen JA, Wang J, Gueyffier F, Thijs L, et al. Meta-analysis of continuous outcomes combining individual patient data and aggregate data. Stat Med 2008;27:1870-93. (Pubitemid 351634244)
54. Mandrekar JN, Mandrekar SJ. Case-control study design: what, when, and why? J Thorac Oncol 2008;3:1371-2.
55. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trials 2010;7:567-73.